Rittenhouse BE, Alolayan S, Segal AR, Eguale T, et al. Reply to "A comment on 'Metformin in the Diabetes Prevention Program 3-year trial: The cost-effectiveness that never was'". Diabetes Obes Metab 2025 Sep 18. doi: 10.1111/dom.70149.
PMID: 40968553